Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Transplantation of Human Adipose-Derived Stem Cells Enhances Remyelination in Lysolecithin-Induced Focal Demyelination of Rat Spinal Cord Publisher Pubmed



Ghasemi N1 ; Razavi S1 ; Mardani M1 ; Esfandiari E1 ; Salehi H1 ; Zarkesh Esfahani SH2
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Anatomical Sciences, School of Medicine, Isfahan University of Medical Sciences, 81744-176 Isfahan, Iran
  2. 2. Department of Biology, Faculty of Science, University of Isfahan, Isfahan, Iran

Source: Molecular Biotechnology Published:2014


Abstract

Adipose-derived stem cells (ADSCs) are a desirable stem cell source in neurodegenerative diseases treatment due to their ability to differentiate into different cell lineages. In this study, we transplanted human ADSCs (hADSCs) into a lysophosphatidylcholine (lysolecithin) model of multiple sclerosis (MS) and determined the efficiency of these cells in remyelination process. Forty adult rats were randomly divided into control, lysolecithin, vehicle, and transplantation groups, and focal demyelination was induced by lysolecithin injection into spinal cord. To assess motor performance, all rats were examined weekly with a standard EAE scoring scale. Four weeks after cell transplantation, to assess the extent of demyelination and remyelination, Luxol Fast Blue staining was used. In addition, immunohistochemistry technique was used for assessment of the presence of oligodendrocyte phenotype cells in damaged spinal cord. Our results indicated that hADSCs had ability to differentiate into oligodendrocyte phenotype cells and improved remyelination process. Moreover, the evaluation of rat motor functions showed that animals which were treated with hADSC compared to other groups had significant improvement (P < 0.001). Our finding showed that hADSCs transplantation for cell-based therapies may play a proper cell source in the treatment of neurodegenerative diseases such as MS. © 2014 Springer Science+Business Media.
Experts (# of related papers)
Other Related Docs
40. Serum Level of Interleukin 36 in Patients With Multiple Sclerosis, Journal of Immunoassay and Immunochemistry (2018)